CC
ALLO icon

Casdin Capital’s Allogene Therapeutics ALLO Stock Holding History

Casdin Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,650,000
Closed -$39.5M – 49
2021
Q4 		$39.5M Buy
2,650,000
+550,000
+26% +$9.7M 1.11% 27
2021
Q3 		$54M Buy
2,100,000
+875,000
+71% +$20.8M 1.34% 27
2021
Q2 		$31.9M Sell
1,225,000
-75,000
-6% -$2.14M 0.81% 32
2021
Q1 		$45.9M Buy
1,300,000
+355,000
+38% +$12M 1.37% 19
2020
Q4 		$23.9M Hold
945,000
– – 0.71% 32
2020
Q3 		$35.6M Buy
945,000
+320,000
+51% +$12.1M 1.6% 20
2020
Q2 		$26.8M Buy
625,000
+125,000
+25% +$4.52M 1.58% 21
2020
Q1 		$9.72M Buy
+500,000
New +$11.9M 1.03% 29

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Casdin Capital's ALLO Position: Q1 2022 in Review

Casdin Capital sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 2,650,000 shares — an estimated $39.5M sold.

Casdin Capital first reported a position in ALLO in Q1 2020 and held it in 8 quarters. The position peaked at $54M in Q3 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

  • Casdin Capital reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Casdin Capital sold 2,650,000 Allogene Therapeutics shares in Q1 2022, an estimated $39.5M.
  • Casdin Capital first reported a position in Allogene Therapeutics in Q1 2020 and held it in 8 quarters.
  • Casdin Capital's Allogene Therapeutics position peaked at $54M in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Casdin Capital's 13F filing for Q1 2022, filed 16 May 2022.